<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The association between cerebrovascular complications and detection of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPA) has been under clinical and immunological investigation during the last ten years </plain></SENT>
<SENT sid="1" pm="."><plain>The occurrence of aPA in coincidence with <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo>, <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> is termed "<z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e>" </plain></SENT>
<SENT sid="2" pm="."><plain>The most important neurological symptoms are recurrent cerebral arterial and venous <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemias</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Especially in the case of young patients with a history of recurrent <z:mpath ids='MPATH_124'>infarcts</z:mpath>, <z:hpo ids='HP_0002076'>migraine</z:hpo>-like <z:hpo ids='HP_0002315'>headaches</z:hpo> and the absence of classical risk factors should lead to a determination of these antibodies </plain></SENT>
<SENT sid="4" pm="."><plain>Although the pathogenetic importance of these antibodies is still unclear, patients positive for them seem to carry a higher cerebrovascular risk and should be observed more cautiously </plain></SENT>
<SENT sid="5" pm="."><plain>More studies are necessary to define the origin of these antibodies and their role in thrombogenesis </plain></SENT>
<SENT sid="6" pm="."><plain>To develop standards for therapeutic management a multicenter study is desirable </plain></SENT>
</text></document>